The companies raised prices a median 4%, though some drugs will cost thousands of dollars more.

The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...